No.5 Issue 22
No.5 Issue 22
- 2024년 11월호
- 해외여행 시 HIV/AIDS 예방
- 마버그열 유행 대비/대응
- 2024년 10월호
- 2024년 9월호
- 오로푸치열 확산, 검사의뢰 안내
- 엠폭스 의심환자 신고안내
- 코로나19 치료제 수급 안정화
- 2024년 8월호
- 2024년 7월호
- 2024년 6월호
- No.8 Issue 12
- 마이코플라스마 폐렴 유행 증가
- No.8 Issue 11
- No.8 Issue 10
- No.8 Issue 09
- No.8 Issue 08
- No.8 Issue 07
- No.8 Issue 06
- No.8 Issue 05
- No.8 Issue 04
- No.8 Issue 03
- No.8 Issue 02
- No.8 Issue 01
- No.7 Issue 09
- No.7 Issue 08
- No.7 Issue 07
- No.7 Issue 06
- No.7 Issue 05
- No.7 Issue 04
- 원숭이두창, 첫 사례 발생
- No.7 Issue 03
- 원숭이 두창(Monkeypox virus)
- No.7 Issue 02
- No.7 Issue 01
- No.6 Issue 24
- No.6 Issue 23
- No.6 Issue 22
- No.6 Issue 21
- No.6 Issue 20
- No.6 Issue 19
- No.6 Issue 18
- No.6 Issue 17
- No.6 Issue 16
- No.6 Issue 15
- No.6 Issue 14
- No.6 Issue 13
- No.6 Issue 12
- 혈소판감소성 혈전증(TTS)
- No.6 Issue 11
- No.6 Issue 10
- No.6 Issue 09
- No.6 Issue 08
- No.6 Issue 07
- No.6 Issue 06
- No.6 Issue 05
- No.6 Issue 04
- No.6 Issue 03
- No.6 Issue 02
- No.6 Issue 01
- No.5 Issue 25
- No.5 Issue 24
- No.5 Issue 23
- No.5 Issue 22
- No.5 Issue 21
- No.5 Issue 20
- No.5 Issue 19
- No.5 Issue 18
- No.5 Issue 17
- No.5 Issue 16
- No.5 Issue 15
- No.5 Issue 14
- No.5 Issue 13
- No.5 Issue 12
- No.5 Issue 11
- No.5 Issue 10
- No.5 Issue 09
- 코로나바이러스감염증-19
- No.5 Issue 08
- No.5 Issue 07
- No.5 Issue 06
- No.5 Issue 05
- No.5 Issue 04
- No.5 Issue 03
- No.5 Issue 02
- 신종 코로나바이러스 감염증
- 신종 코로나바이러스
- No.5 Issue 01
- 중국 폐렴
- No.4 Issue 23
- No.4 Issue 22
- No.4 Issue 21
- No.4 Issue 20
- No.4 Issue 19
- No.4 Issue 18
- No.4 Issue 17
- 전자담배(액상형)
- A형간염
- No.4 Issue 16
- No.4 Issue 15
- No.4 Issue 14
- No.4 Issue 13
- No.4 Issue 12
- No.4 Issue 11
- No.4 Issue 10
- No.4 Issue 9
- No.4 Issue 8
- No.4 Issue 7
- No.4 Issue 6_
- No.4 Issue 5
- No.4 Issue 4
- No.4 Issue 3
- No.4 Issue2
- 홍역
- No.4 Issue1
- No.3 Issue26
- No.3 Issue25
- No.3 Issue24
- No.3 Issue23
- 인플루엔자
- No.3 Issue22
- No.3 Issue21
- No.3 Issue20
- No.3 Issue19
- 메르스
- 메르스
- No.3 Issue18
- No.3 Issue17
- No.3 Issue16
- No.3 Issue15
- No.3 Issue14
- No.3 Issue13
- No.3 Issue12
- No.3 Issue11
- 홍역
- No.3 Issue10
- No.3 Issue9
- No.3 Issue8
- No.3 Issue7
- No.3 Issue6
- No.3 Issue5
- No.3 Issue4
- No.3 Issue3
- No.3 Issue2
- No.3 Issue1
- No.2 Issue24
- No.2 Issue23
- 계절인플루엔자
- No.2 Issue22
- No.2 Issue21
- No.2 Issue20
- No.2 Issue19
- No.2 Issue18
- No.2 Issue17
- No.2 Issue16
- No.2 Issue15
- No.2 Issue14
- No.2 Issue13
- No.2 Issue12
- No.2 Issue11
- 감염병뉴스속보 [메르스]
- No.2 Issue10
- No.2 Issue9
- No.2 Issue8
- No.2 Issue7
- No.2 Issue6
- No.2 Issue5
- No.2 Issue4
- No.2 Issue3
E-NEWS LETTER 2024.06.14
X
귀하의 선택은 오답입니다.
-
1. 인플루엔자 백신
0%
-
2. 폐렴구균백신 (선택)
0%
-
3. 수막알균백신
0%
-
4. b형 페모필루스 인플루엔자 백신
0%
-
5. 대상포진백신(생백신) (정답)
0%
참여수:0명
대상포진백신은 주로 60세 이상에서 적극적으로 권고하며 50-59세 성인은 개별 피접종자의 상태에 따라 대상포진이나 대상포진 후 신경통에 따른 통증에 민감하게 반영할 것으로 예상되는 경우 접종을 권고합니다.
비장절제 후 면역저하가 발생하고 특히 인플루엔자, 폐렴구균, 수막알균, b형 페모필루스 인플루엔자 등에 취약한 것으로 알려져 이에 대한 백신 접종이 필요합니다.
2019년 대한감염학회 성인예방접종표
본 내용은 질병관리청(